Literature DB >> 26334114

Investigating molecular mechanisms for rhamnetin in oxidative damaged cardiomyocytes by microarray data analysis.

Xudong Li1, Junli Gong, Hao Meng, Lei Ji, Lei Chen, Mei Yang, Bushang Liu, Li Geng, Jian Kong.   

Abstract

BACKGROUND: In this study we aimed to investigate molecular mechanisms for rhamnetin in oxidative damaged myocardial cells and provide some new treatment targets for myocardial oxidative stress injury by bioinformatic analysis.
METHODS: Two RNA libraries (control and rhamnetin exposure) from H9c2 cells were constructed and sequenced. After differentially expressed genes (DEGs) identified by NOISeq package, pathways and function analyses were conducted by KEGG and GO BP through DAVID online tool, respectively. Additionally, STRING database was used to construct protein-protein interaction (PPI) network and MCODE was performed for module analysis.
RESULTS: A total of 703 up- and 749 downregulated genes were screened between rhamnetin and control groups. The up-regulated genes were mainly enriched in Adherens junction, Notch signaling pathway and Focal adhesion pathways as well as biological and cellular regulating processes, while the down-regulated genes were mainly enriched in pathways and processes related with oxidative phosphorylation, diseases cell cycle and metabolism. PPI network was constructed with 609 nodes and the top ten nodes were selected with high degrees. Additionally, two modules were obtained with score >6.
CONCLUSIONS: Our study supplied the theoretical basis for uncovering the molecular mechanism of rhamnetin and potential therapeutic targets for myocardial diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26334114

Source DB:  PubMed          Journal:  Minerva Cardioangiol        ISSN: 0026-4725            Impact factor:   1.347


  1 in total

1.  Analysis of Bioactive Components in the Fruit, Roots, and Leaves of Alpinia oxyphylla by UPLC-MS/MS.

Authors:  Li Ying; Deli Wang; Guankui Du
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-09       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.